FGF19 and primary biliary cholangitis: To overcome this defect, NGM282, a nontumorigenic engineered analog of FGF19, was developed to treat PBC, and MGM282 administration for 28 days showed a significant response in ALP and transaminase levels compared with placebos in PBC patients with an inadequate response to UDCA [152].